Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, took control of the cell therapies the company divested during a strategic overhaul and rebranded as Lakefront Biotherapeutics. The move revives the CAR-T research footprint associated with the earlier Galapagos programs, positioning the new entity to re-enter cell-therapy development with renewed focus.